Advertisement

From meta-analysis to the individual patient with atrial fibrillation and coronary artery disease: the complexity of antithrombotic treatment in real-world clinical practice and the need for a tailored approach

  • Giuseppe Boriani
    Correspondence
    Corresponding author: Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Via del Pozzo 71, Modena 41121, Italy.
    Affiliations
    Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy
    Search for articles by this author
  • Jacopo Francesco Imberti
    Affiliations
    Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy
    Search for articles by this author
  • Marco Vitolo
    Affiliations
    Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy
    Search for articles by this author
      The management of antithrombotic therapy in atrial fibrillation (AF) patients presenting with acute coronary syndromes (ACS) and/or undergoing percutaneous coronary interventions (PCI) is highly complex. For this reason, during the last decade cardiovascular research has been focused on finding the best balance between ischemic and hemorrhagic risk in such patients.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Boriani G.
        • Proietti M.
        • Laroche C.
        • Fauchier L.
        • Marin F.
        • Nabauer M.
        • et al.
        Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry.
        Europace. 2018; 20: 747-757
        • Dewilde W.J.
        • Oirbans T.
        • Verheugt F.W.
        • Kelder J.C.
        • De Smet B.J.
        • Herrman J.P.
        • et al.
        Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial.
        Lancet. 2013; 381: 1107-1115
        • Lip G.Y.H.
        • Collet J.P.
        • Haude M.
        • Byrne R.
        • Chung E.H.
        • Fauchier L.
        • et al.
        2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA).
        Europace. 2019; 21: 192-193
        • Kalarus Z.
        • Svendsen J.H.
        • Capodanno D.
        • Dan G.A.
        • De Maria E.
        • Gorenek B.
        • et al.
        Cardiac arrhythmias in the emergency settings of acute coronary syndrome and revascularization: an European Heart Rhythm Association (EHRA) consensus document, endorsed by the European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Acute Cardiovascular Care Association (ACCA).
        Europace. 2019; 21: 1603-1604
        • Vranckx P.
        • Valgimigli M.
        • Eckardt L.
        • Tijssen J.
        • Lewalter T.
        • Gargiulo G.
        • et al.
        Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial.
        Lancet. 2019; 394: 1335-1343
        • Gibson C.M.
        • Mehran R.
        • Bode C.
        • Halperin J.
        • Verheugt F.W.
        • Wildgoose P.
        • et al.
        Prevention of bleeding in patients with atrial fibrillation undergoing PCI.
        N Engl J Med. 2016; 375: 2423-2434
        • Cannon C.P.
        • Bhatt D.L.
        • Oldgren J.
        • Lip G.Y.H.
        • Ellis S.G.
        • Kimura T.
        • et al.
        Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation.
        N Engl J Med. 2017; 377: 1513-1524
        • Lopes R.D.
        • Heizer G.
        • Aronson R.
        • Vora A.N.
        • Massaro T.
        • Mehran R.
        • et al.
        Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation.
        N Engl J Med. 2019; 380: 1509-1524
        • Gargiulo G.
        • Goette A.
        • Tijssen J.
        • Eckardt L.
        • Lewalter T.
        • Vranckx P.
        • et al.
        Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials.
        Eur Heart J. 2019; 40: 3757-3767
        • Potpara T.S.
        • Mujovic N.
        • Proietti M.
        • Dagres N.
        • Hindricks G.
        • Collet J.P.
        • et al.
        Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials.
        Europace. 2020; 22: 33-46
        • Lopes R.D.
        • Hong H.
        • Harskamp R.E.
        • Bhatt D.L.
        • Mehran R.
        • Cannon C.P.
        • et al.
        Safety and efficacy of antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention: a network meta-analysis of randomized controlled trials.
        JAMA Cardiol. 2019; 4: 747-755
        • Rubboli A.
        And now we have the AUGUSTUS … How will it impact on antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention?.
        Eur J Intern Med. 2019; 65: 1-3
        • Ricottini E.
        • Nenna A.
        • Melfi R.
        • Giannone S.
        • Lusini M.
        • Di Sciascio G.
        • et al.
        Antithrombotic treatment in patients with atrial fibrillation undergoing coronary angioplasty: rational convincement and supporting evidence.
        Eur J Intern Med. 2020; https://doi.org/10.1016/j.ejim.2020.02.004
        • Fiedler K.A.
        • Maeng M.
        • Mehilli J.
        • Schulz-Schüpke S.
        • Byrne R.A.
        • Sibbing D.
        • et al.
        Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial.
        J Am Coll Cardiol. 2015; 65: 1619-1629
        • Khan S.U.
        • Osman M.
        • Khan M.U.
        • Khan M.S.
        • Zhao D.
        • Mamas M.A.
        • et al.
        Dual versus triple therapy for atrial fibrillation after percutaneous coronary intervention: a systematic review and meta-analysis.
        Ann Intern Med. 2020; 172: 474-783
        • Rivera-Caravaca J.M.
        • Roldán V.
        • Esteve-Pastor M.A.
        • Valdés M.
        • Vicente V.
        • Lip G.Y.H.
        • et al.
        Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients.
        Thromb Haemost. 2017; 117: 1448-1454
        • Boriani G.
        • Fauchier L.
        • Aguinaga L.
        • Beattie J.M.
        • Blomstrom Lundqvist C.
        • Cohen A.
        • et al.
        European Heart Rhythm Association (EHRA) consensus document on management of arrhythmias and cardiac electronic devices in the critically ill and post-surgery patient, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin American Heart Rhythm Society (LAHRS).
        Europace. 2019; 21: 7-8
        • Sullivan A.E.
        • Nanna M.G.
        • Rao S.V.
        • Cantrell S.
        • Gibson C.M.
        • Verheugt F.W.A.
        • et al.
        A systematic review of randomized trials comparing double versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.
        Catheter Cardiovasc Interv. 2019; : 1-8
        • Capodanno D.
        • Huber K.
        • Mehran R.
        • Lip G.Y.H.
        • Faxon D.P.
        • Granger C.B.
        • et al.
        Management of antithrombotic therapy in atrial fibrillation patients undergoing PCI: JACC state-of-the-art review.
        J Am Coll Cardiol. 2019; 74: 83-99